Cable Hill Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Cable Hill Partners’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,729	Closed	-$22K	–	808
2019 Q1	$22K	Hold	4,729	–	–	0.01%	364
2018 Q4	$20K	Buy	4,729 +450	+11%	+$2.29K	0.01%	352
2018 Q3	$26K	Sell	4,279 -50	-1%	-$384	0.01%	273
2018 Q2	$35K	Hold	4,329	–	–	0.01%	242
2018 Q1	$31K	Buy	4,329 +1,451	+50%	+$9.65K	0.01%	269
2017 Q4	$18K	Buy	2,878 +26	+0.9%	+$158	0.01%	442
2017 Q3	$21K	Buy	2,852 +1,979	+227%	+$12.6K	0.01%	397
2017 Q2	$6K	Sell	873 -3	-0.3%	-$22	﹤0.01%	533
2017 Q1	$8K	Sell	876 -42	-5%	-$419	﹤0.01%	462
2016 Q4	$8K	Buy	+918	New	+$6.79K	﹤0.01%	465

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cable Hill Partners's PGNX Position: Q2 2019 in Review

Cable Hill Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 4,729 shares — an estimated $22K sold.

Cable Hill Partners first reported a position in PGNX in Q4 2016 and held it in 10 quarters. The position peaked at $35K in Q2 2018. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

Cable Hill Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 4,729 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $22K.
Cable Hill Partners first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 10 quarters.
Cable Hill Partners's Progenics Pharmaceuticals Inc position peaked at $35K in Q2 2018.
142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.